A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:60 - Any
Updated:3/13/2019
Start Date:May 21, 2018
End Date:May 2021
Contact:Brian Raether
Email:braether@acadia-pharm.com
Phone:858-768-6074

Use our guide to learn which trials are right for you!

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

The purpose of this study is to assess the safety and tolerability of pimavanserin compared
to placebo in adult and elderly subjects with neuropsychiatric symptoms related to
neurodegenerative disease.


Inclusion Criteria:

1. Can understand the nature of the trial and protocol requirements and provide written
informed consent. If the subject is deemed not competent to provide informed consent,
the following requirements for consent must be met:

1. The subject's legally acceptable representative (LAR) (or study
partner/caregiver, if local regulations allow) must provide written informed
consent

2. The subject must provide written (if capable) informed assent

2. Subject requires some or complete assistance with one or more of the following:

1. Instrumental activities of daily living (communication, transportation, meal
preparation, shopping, housework, managing medications, managing personal
finances) OR

2. Basic activities of daily living (personal hygiene, dressing, eating, maintaining
continence or transferring)

3. Meets clinical criteria for at least one of the following disorders, with or without
cerebrovascular disease (CVD):

1. Parkinson's disease with or without dementia as defined by the Movement Disorder
Society's Task Force

2. Dementia with Lewy bodies (DLB)

3. All-cause dementia, possible or probable Alzheimer's disease (AD)

4. Frontotemporal degeneration spectrum disorders, including possible or probable:

i. Behavioral variant frontotemporal dementia

ii. Progressive supranuclear palsy

iii. Corticobasal degeneration

e. Vascular dementia, including post-stroke dementia multi-infarct dementia and/or
subcortical ischemic vascular dementia (SIVD)

4. Has a designated study partner/caregiver

5. Can come to the clinic for study visits with a study partner/caregiver

6. If the subject is female, she must not be pregnant or breastfeeding. She must also be
of non-childbearing potential (defined as either surgically sterilized or at least 1
year postmenopausal) or must agree to use a clinically acceptable method of
contraception or be abstinent.

7. If the subject is taking an antipsychotic medication at the time of screening, the
antipsychotic medication must be discontinued 2 weeks or 5 half-lives (whichever is
longer)

Exclusion Criteria:

1. Is in hospice, is receiving end-of-life palliative care, or is bedridden

2. Has psychotic symptoms that are primarily attributable to delirium or substance abuse
(i.e., neuropsychiatric symptoms not related to neurodegenerative disease)

3. Has current evidence of an unstable neurological, cardiovascular, respiratory,
gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including
cancer or malignancies that, in the judgment of the Investigator, would jeopardize the
safe participation of the subject in the study or significantly interfere with the
conduct or interpretation of the study

4. Has a known personal or family history of long QT syndrome or family history of sudden
cardiac death

5. Has a clinical significant CNS abnormality that is most likely contributing to the
dementia or findings on MRI or CT including:

1. intracranial mass lesion

2. vascular malformation

3. evidence of >4 hemosiderin deposits

6. The urine drug screen result at Visit 1 (Screening) indicates the presence of
amphetamine/methamphetamine, barbiturates, cocaine, or phencyclidine (PCP). Subjects
who test positive for amphetamines and who have a valid prescription may be retested
if they agree to abstain from the medication for the length of their participation in
the study. The presence of benzodiazepines, marijuana (THC), or opiates does not
necessarily exclude the subject from the study, as assessed by the Investigator in
consultation with the Medical Monitor.

7. Has previously been enrolled in any prior clinical study with pimavanserin or is
currently taking pimavanserinIs judged by the Investigator or the Medical Monitor to
be inappropriate for the study for any reason

Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to
ensure that all criteria for study participation are met. Patients may be excluded from the
study based on these assessments (and specifically, if it is determined that their baseline
health and psychiatric condition do not meet all pre-specified entry criteria).
We found this trial at
13
sites
Shaker Heights, Ohio 44122
?
mi
from
Shaker Heights, OH
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Bourgas,
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Media, Pennsylvania 19063
?
mi
from
Media, PA
Click here to add this to my saved trials
Miami, Florida 33125
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mount Arlington, New Jersey 07856
?
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Newton, Massachusetts 02459
?
mi
from
Newton, MA
Click here to add this to my saved trials
North Palm Beach, Florida 33408
?
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Santa Ana, California 92705
?
mi
from
Santa Ana, CA
Click here to add this to my saved trials
3201 Wedgewood Lane
The Villages, Florida 32162
?
mi
from
The Villages, FL
Click here to add this to my saved trials